Curasight Yönetim

Yönetim kriter kontrolleri 2/4

Curasight CEO'su Ulrich Krasilnikoff, Jan2016 tarihinde atandı, in görev süresi 8.83 yıldır. şirketin hisselerinin 19.25% doğrudan sahiptir ve bu hisselerin değeri DKK 43.39M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.8 yıl ve 8.8 yıldır.

Anahtar bilgiler

Ulrich Krasilnikoff

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	8.8yrs
CEO sahipliği	19.2%
Yönetim ortalama görev süresi	8.8yrs
Yönetim Kurulu ortalama görev süresi	8.8yrs

Son yönetim güncellemeleri

Recent updates

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

Aug 29

CEO

Ulrich Krasilnikoff (57 yo)

8.8yrs

Görev süresi

Mr. Ulrich Alexander Krasilnikoff has been Chief Executive Officer, Chief Financial Officer and Executive Director at Curasight A/S since 2016. Mr. Krasilnikoff served as an Associate Partner at Capidea Ma...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ulrich Krasilnikoff	CEO, CFO & Executive Director	8.8yrs	Veri yok	19.25% DKK 43.4m
Jacob Madsen	Co-Founder & Director CMC	11.8yrs	Veri yok	4.4% DKK 9.9m
Andreas Kjaer	Co-Founder	11.8yrs	Veri yok	29.09% DKK 65.6m
Hanne Jensen	Chief Development Officer & COO	2.8yrs	Veri yok	0.19% DKK 433.7k
Nic Gillings	Head of Quality Assurance & Regulatory Affairs	3.4yrs	Veri yok	Veri yok

8.8yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: CURAS 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ulrich Krasilnikoff	CEO, CFO & Executive Director	8.8yrs	Veri yok	19.25% DKK 43.4m
Andreas Kjaer	Co-Founder	11.8yrs	Veri yok	29.09% DKK 65.6m
Kirsten Drejer	Chairman of the Board	3.4yrs	Veri yok	0.019% DKK 43.4k
Lars Trolle	Independent Deputy Chairman of the Board	10.8yrs	Veri yok	2.84% DKK 6.4m
Charlotte Vedel	Independent Deputy Chairman of the Board	4.8yrs	Veri yok	0.19% DKK 433.7k

8.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CURAS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.8 yıldır).

Curasight Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Curasight A/S Announces Board Changes

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S, Annual General Meeting, Mar 24, 2022

Recent updates

Curasight A/S Announces Clinical Supply Agreement with Curium for uTREAT® Development and Commercialization

Curasight A/S Announces International Patent Application for uTREAT® to Broaden IP Protection

Curasight A/S Publishes Clinical Phase II Trial of uPAR-PET in Brain Cancer Patients; Data Supports Development of uTREAT for Brain Cancer

New major risk - Financial position

Curasight A/S to Report Q3, 2024 Results on Nov 21, 2024

Curasight (NGM:CURAS) Is Making Moderate Use Of Debt

New minor risk - Shareholder dilution

Curasight A/S to Report Q2, 2024 Results on Aug 22, 2024

Curasight A/S to Report Q3, 2024 Results on Jul 02, 2024

New major risk - Share price stability

New major risk - Financial position

Curasight A/S to Report Q1, 2024 Results on May 23, 2024

Less than half of directors are independent

Curasight A/S Announces Approval of Clinical Trial Application (CTA) for Phase 2 Trial with uTRACE in Prostate Cancer Patients

Curasight A/S Announces Board Changes

Curasight A/S has withdrawn its Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S, Annual General Meeting, Mar 21, 2024

Curasight A/S has filed a Follow-on Equity Offering in the amount of SEK 51.155712 million.

Curasight A/S to Report Fiscal Year 2023 Results on Feb 22, 2024

Curasight Gears Up for Phase II Study in Prostate Cancer

Curasight A/S to Report Q3, 2023 Results on Nov 24, 2023

New minor risk - Share price stability

Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer (NSCLC)

Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague

Curasight A/S to Report Q2, 2023 Results on Aug 24, 2023

Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer

Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)

Curasight A/S to Report Fiscal Year 2022 Results on Feb 23, 2023

Curasight A/S Initiates Pre-Clinical Studies with uTREAT Therapy in Head and Neck Cancer and Neuroendocrine Tumors

Curasight A/S Announces Recruitment Completes in uPAR-PET Study in Brain Cancer

Curasight A/S, Annual General Meeting, Mar 24, 2022

Curasight A/S Announces Positive Data of uTREAT® in Glioblastoma Provides "Green Light" to Proceed with Next Steps

New 90-day high: kr.41.50

New 90-day high: kr.34.45

Curasight Announces Results from Phase II Study in Prostate Cancer to Be Published in the Journal of Nuclear Medicine

Curasight A/S to Report Q1, 2021 Results on May 20, 2021

Curasight A/S Initiates Pre-Clinical Study on Therapy in Brain Cancer and Signs CRO-Agreement

Curasight A/S has completed an IPO in the amount of DKK 32.688 million.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş